Roivant does not view - and has never viewed - Axovant as simply a 'vehicle' for developing intepirdine, but instead as a platform for the development of high-impact drugs in dementia and the neuroscience field more generally. — Vivek Ramaswamy Copy Share Image
The problem we are trying to solve is that of drugs that would have never seen the light of day for reasons that have… — Vivek Ramaswamy Copy Share Image
Roivant does not view - and has never viewed - Axovant as simply a 'vehicle' for developing intepirdine, but instead as a platform for… — Vivek Ramaswamy Copy Share Image
The 'Living-Wage Campaign' at Harvard is like a Boston winter: you know it's going to strike, but wonder only when and how hard. — Vivek Ramaswamy Copy Share Image
I would think the correlation between an era of increased globalization and an increased desire to participate in an entrepreneurial endeavor is not a… — Vivek Ramaswamy Copy Share Image
There is no doubt that the Mindset failure is a major setback for Axovant, but it is not the end of the road. — Vivek Ramaswamy Copy Share Image
I've said all along that we're building Axovant as a lasting company for the long run, not to hand over that upside to a… — Vivek Ramaswamy Copy Share Image
I would not have had the same personal commitment to Alzheimer's disease if it had not been for my mother and my upbringing. — Vivek Ramaswamy Copy Share Image
From a personal standpoint, I consider myself much more of an accidental entrepreneur. I was involved in the entrepreneurship club at Harvard, but I… — Vivek Ramaswamy Copy Share Image
I believe the pharma company of the future isn't going to be old-school. — Vivek Ramaswamy Copy Share Image
In contrast to how tech firms want to disrupt and break things - developing drugs must be incremental and step-by-step. This is the kind… — Vivek Ramaswamy Copy Share Image
I think dementia is the major healthcare threat to our economy and our security. It's a ticking time bomb - we have a whole… — Vivek Ramaswamy Copy Share Image
The thing in Alzheimer's disease to remember, and we remember this all the time at Axovant, is we don't fully understand the way the… — Vivek Ramaswamy Copy Share Image
